Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Invest Dermatol. 2004 Feb;122(2):337-41.

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Author information

  • 1Wellman Laboratories, Department of Dermatology, Massachusetts General Hospital Melanoma Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

Abstract

Extant evidence implicates growth factor signaling in the pathogenesis of many tumor types, including cutaneous melanoma. Recently, reciprocal activating mutations of NRAS and BRAF were found in benign melanocytic nevi and cutaneous melanomas. We had previously reported a similar epistatic relationship between activating NRAS mutations and inactivating PTEN/MMAC1 alterations. We thus hypothesized that BRAF and PTEN/MMAC1 mutations may cooperate to promote melanoma tumorigenesis. Overall, 40 of 47 (85%) melanoma cell lines and 11 of 16 (69%) uncultured melanoma metastases had mutations in NRAS, BRAF, or PTEN/MMAC1. NRAS was exclusively mutated in nine of 47 (19%) cell lines and two of 16 (13%) metastases, whereas BRAF was solely mutated in 28 of 47 (60%) cell lines and nine of 16 (56%) metastases. In the 12 of 15 melanoma cell lines (80%) and two of two melanoma metastases with PTEN alterations, BRAF was also mutated. These findings suggest the existence of possible cooperation between BRAF activation and PTEN loss in melanoma development.

Comment in

  • Deletion of PTENP1 pseudogene in human melanoma. [J Invest Dermatol. 2011]
PMID:
15009714
[PubMed - indexed for MEDLINE]
PMCID:
PMC2586668
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk